Skip to content

Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01233934
Enrollment
90
Registered
2010-11-03
Start date
2011-02-28
Completion date
2011-07-31
Last updated
2010-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insect Bites

Keywords

Insect bites, Dexchlorpheniramine, Gel, Cream

Brief summary

Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms. Dexchlorpheniramine maleate 1% cream is a topical anti-histaminic formulation approved by ANVISA in Brazil for the relief of skin irritation and allergies, including the ones caused by insect bites. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% gel) with the standard preparation (1% cream) for the relief of insect bite related symptoms and to demonstrate the safety of both preparations.

Interventions

Small amount applied over the lesion twice a day for 7 days.

Small amount applied over the lesion twice a day for 7 days.

Sponsors

Mantecorp Industria Quimica e Farmaceutica Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Presence of papules resulting from insect bites within the last 72 hours; * Presence of symmetric lesions to compare one side to the other; * Compliance of the subject to the treatment protocol; * Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old.

Exclusion criteria

* Pregnancy or risk of pregnancy; * Lactation; * Use of topical or systemic anti-inflammatory, anti-histaminics or immunosuppressive drugs within the last 48 hours prior to the study; * History of atopy or allergic diseases; * History of allergy of any component of the formulations; * Other conditions considered by the investigator as reasonable for non-eligibility.

Design outcomes

Primary

MeasureTime frame
Pruritus Intensity at Insect Bite Site, Evaluated With a 10 Point Visual Analogic Scale (VAS)7 days

Secondary

MeasureTime frame
Composite Clinical Evaluation of Erythema, Pruritus and Papule Formation, Performed by the Investigator Using a 4-point Scale for Each One of the Parameters (Absent, Mild, Moderate, Intense). This Evaluation Constitutes the Insect Bite Score.7 days

Countries

Brazil

Contacts

Primary ContactSergio Schalka, MD
medci004@terra.com.br551136811334

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026